Inpharmus is steadily increasing its presence in global healthcare by using its strong knowledge of rare diseases and cancer treatments, along with a team of skilled professionals and a focus on innovation. Right now, the company sells its products in important areas such as the Middle East, Russia, Africa, and Turkey, which are collectively referred to as the MERAT Region. With a clear plan for growth, Inpharmus is aiming to reach $500 million in international sales by 2030.
Health Technology Insights: Exxat and Powerback Rehab Partner to Enhance Clinical Education
Since it was founded in 2013 with the goal of offering effective healthcare solutions worldwide, Inpharmus has established itself as a strong player in the fields of rare diseases and oncology. The company combines advanced products, medical knowledge, and a global outlook, making it a dependable partner in these complex areas of care. After experiencing significant growth in the Gulf region and discovering new chances in the CIS region, Inpharmus has expanded further by opening a new office in Moscow. This new location joins its existing offices in Istanbul and Dubai. The company is now also aiming to become a unicorn, targeting a $1 billion valuation by the end of the decade, supported by its commitment to quality and expertise.
Health Technology Insights: Distalmotion Teams Up with First Citizens Bank for Flexible Surgery Tech Financing
Ismet Ince, the CEO of Inpharmus, believes the company’s success can be attributed to its science-based approach and its ability to quickly adapt and solve problems. He mentioned that this mindset, combined with a focus on people and communities, has helped Inpharmus become a trusted name both locally and internationally. According to Ince, this focus has created a stable corporate base and has been essential in supporting long-term global expansion. He also explained the origin of the company’s name, saying it represents a combination of innovation, pharmaceutical knowledge, and teamwork. Ince emphasized that this philosophy helps the company align global strategies with the specific needs of local markets, allowing for growth in partnership with stakeholders.
As part of its growth model, Inpharmus places a strong emphasis on global partnerships. The company is building stronger relationships with healthcare institutions, government agencies, hospitals, and professionals around the world. Several joint research and development projects with international partners are already in progress. Ince pointed out that their goal is not just to supply medicine, but to be known as a real healthcare partner that provides solutions, shares knowledge, and adds value to every collaboration. He noted that the company’s focus is to support clinical research, promote integrated healthcare models, and raise the profile of the region’s medical talent on the global stage.
One of Inpharmus’ main focuses is innovation, especially in rare diseases and oncology. These are areas where patients often have limited access to treatments, and Inpharmus aims to address this with a flexible and proactive approach. Ince highlighted the company’s commitment to shaping the future of medicine, particularly in gene and personalized therapies. He pointed to the company’s progress in tackling Familial Mediterranean Fever (FMF), a genetic condition common in the MENA region. For the first time in Turkey, Inpharmus successfully completed a Phase I clinical trial of a biological treatment for FMF, proving the product’s safety. The subsequent Phase II trial showed encouraging results in terms of dosage and effectiveness. The project is now in an extension phase, with regulatory approvals being pursued at the same time.
Health Technology Insights: AEYE Health Names Yonatan Raz-Fridman as Chief Business Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
